Lazard Asset Management
XENE icon

Lazard Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Lazard Asset Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.66M Sell
44,125
-6,630
-13% -$368K ﹤0.01% 848
2026
Q1 		$2.95M Sell
50,755
-27,908
-35% -$1.29M ﹤0.01% 742
2025
Q4 		$3.53M Buy
+78,663
New +$3.3M 0.01% 665
2020
Q4 		– Sell
-705
Closed -$7K – 2006
2020
Q3 		$7K Buy
+705
New +$8.29K ﹤0.01% 1522

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Lazard Asset Management's XENE Position: Q2 2026 in Review

Lazard Asset Management reduced its Xenon Pharmaceuticals (XENE) stake by 13% in Q2 2026, selling an estimated $368K and leaving 44,125 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #848.

Lazard Asset Management first reported a position in XENE in Q3 2020 and has held it in 4 quarters since. The position peaked at $3.53M in Q4 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Lazard Asset Management held 44,125 shares of Xenon Pharmaceuticals worth $2.66M as of Q2 2026.
  • Lazard Asset Management sold 6,630 Xenon Pharmaceuticals shares in Q2 2026, an estimated $368K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #848 holding.
  • Lazard Asset Management first reported a position in Xenon Pharmaceuticals in Q3 2020 and has held it in 4 quarters since.
  • Lazard Asset Management's Xenon Pharmaceuticals position peaked at $3.53M in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.